By focusing on these 17 high-priority pathogens, WHO is leading the way for a world that is better prepared, more resilient, and healthier for ... Nov 09
Lungershausen said Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.... Mar 29
Know the major difference between the Coronavirus (COVID-19) and Human Immunodeficiency Virus (HIV). Furthermore, learn about the ways in which one can protect themselves ... Mar 29
Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV... Jan 15
... Jan 13
This authorization represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the ... Dec 21
Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.... Dec 11
Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option with Focus on Women... Nov 16
Dolutegravir is the first integrase inhibitor available as a dispersible tablet for children... Nov 13
ViiV Healthcare announced CHMP issed positive opinion recommending Vocabria in combination with Rekambys and Edurant for the treatment of HIV-1 ... Oct 16
GSK two drug combination is as good as 3 drug regimen which is presently continued for HIV 1 patients... Oct 09
Merck, today announced Week 96 data from the Phase 2b trial evaluating the efficacy and safety of islatravir for HIV-1 infections... Oct 08
Findings showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine continued to offer non-inferior efficacy... Oct 05
Data presented may shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV ... Oct 01
Cobas 6800/8800 gets USFDA approval for the machines are also being used in India for Covid detection... Sep 05
CABENUVA reduces treatment dosing days from 365 to 12 per year ​... Mar 21
New starin of HIV detected... Jan 25
-Advertisements-